Earkart Limited
Earkart Manufacture and distribute modern hearing aids and related accessories at affordable price across India. Along with our own manufactured hearing aid, we also trade in hearing aid, parts and accessories of other brands manufactured in India and abroad.(Source : 202509 Prospectus Page No: 20)
- Market Cap ₹ 165 Cr.
- Current Price ₹ 120
- High / Low ₹ 266 / 104
- Stock P/E 33.5
- Book Value ₹ 46.8
- Dividend Yield 0.00 %
- ROCE 17.5 %
- ROE 11.7 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Working capital days have increased from 161 days to 237 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Equipment & Supplies Medical Equipment & Supplies
Part of BSE SME IPO
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 5.66 | 28.92 | 31.75 | 43.11 | 54.04 | |
| 5.52 | 27.29 | 28.17 | 33.32 | 45.69 | |
| Operating Profit | 0.14 | 1.63 | 3.58 | 9.79 | 8.35 |
| OPM % | 2.47% | 5.64% | 11.28% | 22.71% | 15.45% |
| 0.04 | 0.05 | 0.21 | 0.09 | 0.11 | |
| Interest | 0.01 | 0.08 | 0.36 | 0.44 | 0.54 |
| Depreciation | 0.06 | 0.15 | 0.19 | 0.42 | 0.66 |
| Profit before tax | 0.11 | 1.45 | 3.24 | 9.02 | 7.26 |
| Tax % | 0.00% | 9.66% | 5.86% | 23.61% | 31.96% |
| 0.11 | 1.31 | 3.06 | 6.88 | 4.93 | |
| EPS in Rs | 22.00 | 262.00 | 612.00 | 6.59 | 3.58 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 23% |
| TTM: | 25% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 56% |
| TTM: | -28% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 22% |
| Last Year: | 12% |
Balance Sheet
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 0.05 | 0.05 | 0.05 | 10.44 | 13.75 |
| Reserves | 4.72 | 6.49 | 12.97 | 9.48 | 50.59 |
| 0.27 | 1.23 | 4.02 | 4.96 | 0.00 | |
| 0.91 | 6.96 | 2.21 | 5.41 | 5.15 | |
| Total Liabilities | 5.95 | 14.73 | 19.25 | 30.29 | 69.49 |
| 0.22 | 0.25 | 1.06 | 1.17 | 5.88 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 1.46 | 0.10 | 0.19 | 0.83 | 0.15 |
| 4.27 | 14.38 | 18.00 | 28.29 | 63.46 | |
| Total Assets | 5.95 | 14.73 | 19.25 | 30.29 | 69.49 |
Cash Flows
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| -2.83 | -0.30 | -1.00 | 0.71 | -12.56 | |
| -1.78 | 0.40 | -1.29 | -1.32 | -5.18 | |
| 4.68 | 0.41 | 3.08 | -0.41 | 39.06 | |
| Net Cash Flow | 0.07 | 0.51 | 0.80 | -1.01 | 21.32 |
| Free Cash Flow | -3.11 | -0.48 | -1.99 | 0.18 | -17.93 |
| CFO/OP | -2,007% | -17% | -22% | 30% | -122% |
Ratios
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 104.47 | 59.32 | 72.89 | 157.23 | 142.31 |
| Inventory Days | 138.26 | 100.90 | 113.12 | 95.52 | 121.11 |
| Days Payable | 92.17 | 107.33 | 19.28 | 44.04 | 19.96 |
| Cash Conversion Cycle | 150.56 | 52.89 | 166.73 | 208.70 | 243.46 |
| Working Capital Days | 192.17 | 60.83 | 108.06 | 139.02 | 237.21 |
| ROCE % | 23.89% | 29.02% | 45.13% | 17.48% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Sep 2025 | |
|---|---|---|---|---|
| Revenue Mix - Government Sector % |
|
|||
| Large Government Orders (ALIMCO/GeM) Units |
||||
| Revenue Mix - Private Sector % |
||||
| Shop-in-Shop (SIS) Clinics Number |
||||
| Annual Production Capacity (Hearing Aids) Units |
||||
| Dealer Partners Number |
||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Acquisition
30 May - Earkart approved two WOS incorporations: pharma and healthcare, with Rs1 lakh initial capital each.
-
Declaration Pursuant To Regulation 33(3)(D) Of The SEBI(LODR) Regulations, 2015 As Amended In Respect Of Audit Report With Unmodified Opinion For The Financial Year Ended 31 March 2026
29 May - Auditor issued unmodified opinion for audited results year ended 31 March 2026.
-
Financial Results For The Half Year Ended And Year Ended On 31 March 2026
29 May - Board approved audited standalone FY2026 results and appointed internal and secretarial auditors for FY2026-27.
-
Board Meeting Outcome for Outcome Of Board Meeting Dated 29 May 2026 Pursuant To Regulation 30 Of SEBI (LODR) Regulation, 2015
29 May - Board approved audited standalone results for FY2026 and appointed internal and secretarial auditors for FY2026-27.
-
Board Meeting Intimation for Pursuant To Regulation 29(1) Of The SEBI (LODR) Regulation, 2015, We Hereby Inform You That A Meeting Of The Board Of The Company Is Scheduled To Be Held On Friday, 29 May 2026.
26 May - Board meeting on 29 May 2026 to approve FY26 audited financials and fix 5th AGM date.
Annual reports
No data available.
Concalls
-
Jan 2026TranscriptPPTREC
-
Dec 2025Transcript PPT
Business Profile[1]
Earkart manufactures and distributes modern hearing aids (BTE & RIC) and accessories, trades third-party hearing aids and parts, and also supplies mobility aids (foldable walkers) and educational/therapy kits (MSIED and TLM) for children with disabilities.